Target intelligence / Profile preview

Interleukin-21 receptor–common gamma-chain complex (IL-21R–γc complex)

Target
IL-21R–γc complex
Molecular classification
Receptor, Type I cytokine receptor, Cell surface receptor, JAK-STAT pathway receptor
01

Overview

The **Interleukin-21 receptor–common gamma-chain complex** is a high-affinity heterodimeric cell surface receptor comprised of the private interleukin-21 receptor (IL-21R) and the common gamma chain (γc, also called IL2RG)[1][3][4][8]. This complex is essential for IL-21-mediated signal transduction in both innate and adaptive immune cells. Upon binding of IL-21, the receptor activates downstream pathways primarily via JAK1 and JAK3 tyrosine kinases, leading to phosphorylation of STAT1, STAT3, and sometimes STAT5 or STAT4, depending on cell type[4][6][8]. The common gamma chain is also shared with other cytokine receptors such as IL-2, IL-4, IL-7, IL-9, and IL-15, underlining its central role in immunological signaling[1][7][8]. Dysregulation of IL-21 signaling via this complex is implicated in numerous pathological states, including cancer, immune dysregulation, inflammation, and cardiovascular disease, and makes it an important therapeutic target in immune modulation[2][4][6].

Other names
Interleukin-21 receptor complexIL-21R–IL2RG complexIL-21 receptor / common γ-chain complexIL-21R–γc heterodimer
02

Mechanism of action

Antagonistic antibodies block IL-21 binding, preventing downstream signaling[1][7]. JAK inhibitors suppress receptor-mediated activation of JAK-STAT pathways[7][8].

03

Biological functions

Immune responseSignal transductionCell proliferationApoptosisDifferentiation of B cells, T cells, and NK cells
04

Disease associations

CancerInflammationInfectionAutoimmune diseaseCardiovascular disease (e.g., myocardial hypertrophy and fibrosis)
05

Safety considerations

Potential for immunosuppression (due to broad role in immune regulation)[6][7]Risk of infection when blocking IL-21/IL-21R pathways[6]Possible exacerbation of autoimmune or inflammatory disease if pathway is hyperactivated[2][4]
06

Interacting drugs

No FDA-approved drugs specifically targeting this complex; experimental antagonistic antibodies or inhibitors exist, such as those targeting IL-21 or the IL-21/IL-21R interaction[2][6][7].

1 more in the full profile.

07

Biomarkers

IL-21 and IL-21R expression in immune or cardiac cells can serve as biomarkers of pathway activation[2][4].STAT3 phosphorylation status (as readout of receptor activity)[2][4].

Beyond the preview

Go deeper on Interleukin-21 receptor–common gamma-chain complex (IL-21R–γc complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-21 receptor–common gamma-chain complex (IL-21R–γc complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call